10 Implementation difficulties Difficulty in identifying DTCs that are contrary to the agreement Difficulty in identifying alternative strategies to achieve the same objective difficulties in accounting for non-conditional results as the financial crisis in Asia and Latin America Difficulties in meeting transitional periods LDCs are not able to identify measures incompatible with the TRIPS agreement and are therefore unable to identify inconsistent measures with the TRIPS agreement ON TRIPS , to meet the notification deadline. The prohibition of „local content“ requirement. However, since it is based on the interests of FDI, the agreement did not bring the expected benefits of Denhost Enpros: reducing the balance-of-payments benefits of foreign direct investment To reduce competition with domestic producers Cons: Reducing the benefits of foreign direct investment for host host hosts trying to impose restrictions on the activities of MNEs in order to derive more benefits that presides over the interests of MNEs in the face of irrefutable social effects – industry will not be in the right place. Improving its international competitiveness MNE wants to reduce the diffusion of technologies and maximize its profits by making its value chain efficient. Individual Companies Article II „… 2.The related agreements and related legal instruments in Schedules 1, 2 and 3 (`multilateral`) are included below. With the TRIPS agreement, intellectual property rights have been integrated into the multilateral trading system for the first time and remains the most comprehensive multilateral IP agreement to date. In 2001, developing countries, fearing that developed countries had insisted on too narrow a reading of the TRIPS trip, launched a series of discussions that culminated in the Doha Declaration. The Doha Declaration is a WTO DECLARATION that clarifies the scope of the TRIPS agreement, which states, for example, that TRIPS can and should be interpreted in light of the objective of „promoting access to medicines for all“. Trips-plus conditions, which impose standards beyond TRIPS, have also been verified.
 These free trade agreements contain conditions that limit the ability of governments to introduce competition for generic drug manufacturers. In particular, the United States has been criticized for promoting protection far beyond the standards prescribed by the TRIPS. The U.S. free trade agreements with Australia, Morocco and Bahrain have expanded patentability by making patents available for new uses of known products.  The TRIPS agreement authorizes the granting of compulsory licences at the discretion of a country. The terms of trips plus in the U.S. Free Trade Agreement with Australia, Jordan, Singapore and Vietnam have limited the application of mandatory licences to emergencies, remedies for cartels and abuse of dominance, and cases of non-commercial public use.  In addition to the basic intellectual property standards created by the TRIPS agreement, many nations have engaged in bilateral agreements to adopt a higher level of protection. This collection of standards, known as TRIPS or TRIPS-Plus, can take many forms.  The general objectives of these agreements are as follows: under the TRIPS agreement, members are required to notify the WTO Goods Trade Council of their existing DTUs that are incompatible with the agreement.
The IP sections covered by this agreement are as follows: the 2002 Doha Declaration confirmed that the TRIPS agreement should not prevent members from taking the necessary measures to protect public health.